Literature DB >> 6276950

Angiotensin converting enzyme activity in human serum: relationship to enzyme inhibitor in vivo and in vitro.

B N Swanson, M Hichens, P Mojaverian, R K Ferguson, P H Vlasses, M Dudash.   

Abstract

Quantitative relationships between angiotensin converting enzyme activity in human serum and concentration of an enzyme inhibitor, the active diacid metabolite of MK-421 [N-(S-1-carbethoxy-3-phenylpropyl)-S-alanyl-S-proline maleate], were defined. Dose-response curves were generated in vitro by adding the diacid metabolite (DM) to serum (ID50 = to 6x10-9 M); l0-15% of initial activity was nonsuppressible. DM an converting enzyme activity were also measured in serum from hypertensive subjects receiving oral MK-421. The dose-response curve for serum samples following single doses of MK-421 (ID50 = 6x10-9M), was similar to curves generated in vitro while the curve for sample following chronic therapy suggested a small decrease in inhibitory potency.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6276950

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  4 in total

1.  Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects.

Authors:  K Weisser; J Schloos; K Lehmann; R Düsing; H Vetter; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients.

Authors:  K Weisser; J Schloos; S Jakob; W Mühlberg; D Platt; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Enalapril maleate and a lysine analogue (MK-521): disposition in man.

Authors:  E H Ulm; M Hichens; H J Gomez; A E Till; E Hand; T C Vassil; J Biollaz; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

4.  Effect of captopril and hydrochlorothiazide on the response to pressor agents in hypertensives.

Authors:  R J Fruncillo; H H Rotmensch; P H Vlasses; J R Koplin; B N Swanson; R K Ferguson
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.